JP2022518526A5 - - Google Patents

Info

Publication number
JP2022518526A5
JP2022518526A5 JP2021543144A JP2021543144A JP2022518526A5 JP 2022518526 A5 JP2022518526 A5 JP 2022518526A5 JP 2021543144 A JP2021543144 A JP 2021543144A JP 2021543144 A JP2021543144 A JP 2021543144A JP 2022518526 A5 JP2022518526 A5 JP 2022518526A5
Authority
JP
Japan
Prior art keywords
substituted
compounds
alkyl
phenyl
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021543144A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022518526A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2020/051836 external-priority patent/WO2020152361A1/en
Publication of JP2022518526A publication Critical patent/JP2022518526A/ja
Publication of JP2022518526A5 publication Critical patent/JP2022518526A5/ja
Pending legal-status Critical Current

Links

JP2021543144A 2019-01-25 2020-01-24 カルバメート誘導体およびその使用 Pending JP2022518526A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962796724P 2019-01-25 2019-01-25
US62/796,724 2019-01-25
PCT/EP2020/051836 WO2020152361A1 (en) 2019-01-25 2020-01-24 Carbamate derivatives and uses thereof

Publications (2)

Publication Number Publication Date
JP2022518526A JP2022518526A (ja) 2022-03-15
JP2022518526A5 true JP2022518526A5 (enExample) 2023-01-31

Family

ID=69375331

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021543144A Pending JP2022518526A (ja) 2019-01-25 2020-01-24 カルバメート誘導体およびその使用

Country Status (13)

Country Link
US (1) US20220098159A1 (enExample)
EP (1) EP3914351A1 (enExample)
JP (1) JP2022518526A (enExample)
KR (1) KR20210131329A (enExample)
CN (1) CN113660983A (enExample)
AU (1) AU2020211361A1 (enExample)
BR (1) BR112021014389A2 (enExample)
CA (1) CA3126495A1 (enExample)
EA (1) EA202192057A1 (enExample)
IL (1) IL284843A (enExample)
MX (1) MX2021008930A (enExample)
SG (1) SG11202107653RA (enExample)
WO (1) WO2020152361A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10118890B2 (en) 2014-10-10 2018-11-06 The Research Foundation For The State University Of New York Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration
GB201712282D0 (en) 2017-07-31 2017-09-13 Nodthera Ltd Selective inhibitors of NLRP3 inflammasome

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
NO921449L (no) * 1991-04-17 1992-10-19 American Home Prod Karbamater av rapamycin
US5763263A (en) 1995-11-27 1998-06-09 Dehlinger; Peter J. Method and apparatus for producing position addressable combinatorial libraries
WO1999012534A1 (en) * 1997-09-10 1999-03-18 Ono Pharmaceutical Co., Ltd. Peroxisome proliferator-activated receptor controllers
US20020002200A1 (en) * 2000-02-04 2002-01-03 Bishwagit Nag Novel diphenylethylene compounds
DE10063008A1 (de) * 2000-12-16 2002-06-20 Merck Patent Gmbh Carbonsäureamidderivate
KR102727059B1 (ko) * 2015-02-16 2024-11-05 더 유니버서티 어브 퀸슬랜드 설포닐우레아와 관련 화합물 및 그 용도
WO2017035413A2 (en) * 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Carbamate, ester, and ketone compounds for treatment of immune and inflammatory disorders
CN109071454B (zh) * 2016-02-16 2023-02-17 昆士兰大学 磺酰脲和相关化合物及其用途
EP3571191A1 (en) * 2017-01-20 2019-11-27 Pfizer Inc 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives as magl inhibitors
GB2561540A (en) * 2017-03-13 2018-10-24 Nodthera Ltd Chemical compounds
EP3634951B8 (en) * 2017-06-09 2024-08-21 Zydus Lifesciences Limited Novel substituted sulfoximine compounds
GB201712282D0 (en) 2017-07-31 2017-09-13 Nodthera Ltd Selective inhibitors of NLRP3 inflammasome

Similar Documents

Publication Publication Date Title
JP7738910B2 (ja) 置換ピリダジン化合物
JP7301840B2 (ja) Ｌｐａアンタゴニストとしてのイソキサゾールｎ結合カルバモイルシクロヘキシル酸
US6797706B1 (en) Heterocyclecarboxamide derivative
EP1932840B1 (en) Nitrogen-containing heterocyclic compound and pharmaceutical application thereof
JP2022513959A5 (enExample)
JP2025011095A (ja) パンテテイン誘導体及びその使用
EA036637B1 (ru) Гетероциклические спиросоединения, ингибирующие моноацилглицерин-липазу
JP2018510207A5 (enExample)
US8124778B2 (en) Tricyclic inhibitors of fatty acid amide hydrolase
RS62164B1 (sr) Sulfoniluree i srodna jedinjenja i njihova upotreba
TW202227389A (zh) 新穎化合物
KR20190077544A (ko) Magl 억제제
JP2010522710A (ja) Ｐ２ｘ７調節因子としてのオキサゾリジンおよびモルホリンカルボキサミド誘導体
JP2012524743A (ja) Ｈｓｐ９０阻害剤としてのレゾルシノール誘導体
JP2014523400A (ja) 芳香族アミド類およびそれらの使用
JP2023540733A5 (enExample)
JP6413032B2 (ja) 新規ｄｇａｔ２阻害剤
JP2022536160A5 (enExample)
JP2024513227A5 (enExample)
WO2017188357A1 (ja) 置換ジヒドロピロロピラゾール化合物および他の乾癬治療薬が組み合わせて投与される医薬組成物
JP2022518526A5 (enExample)
WO2020100944A1 (ja) ジヒドロピロロピラゾール誘導体
BR112020016784A2 (pt) Composto de di-hidropirimidinona ou di-hidropirimidinona condensado ao anel saturado e uso farmacêutico do mesmo
JP2022535956A5 (enExample)
JP7682813B2 (ja) スルホニル尿素誘導体及びその使用